This paper is in the following e-collection/theme issue:

Non-Randomized Study Protocols and Methods (Non-eHealth) (673) Clinical Cancer Research (114)

Published on in Vol 11, No 7 (2022): July

Preprints (earlier versions) of this paper are available at https://preprints.jmir.org/preprint/35565, first published .
Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Salivary Dysfunctions and Consequences After Radioiodine Treatment for Thyroid Cancer: Protocol for a Self-Controlled Study (START Study)

Authors of this article:

Clémence Baudin1 Author Orcid Image ;   Charlotte Lussey-Lepoutre2, 3 Author Orcid Image ;   Alice Bressand4 Author Orcid Image ;   Camille Buffet5 Author Orcid Image ;   Fabrice Menegaux5, 6 Author Orcid Image ;   Marine Soret6, 7 Author Orcid Image ;   David Broggio8 Author Orcid Image ;   Céline Bassinet9 Author Orcid Image ;   Christelle Huet9 Author Orcid Image ;   Gemma Armengol10 Author Orcid Image ;   Laurence Leenhardt5 Author Orcid Image ;   Marie-Odile Bernier1 Author Orcid Image
Article Authors Cited by (8) Tweetations (5) Metrics

Journals

  1. Sunavala-Dossabhoy G, Petti S. Effect of recombinant human thyroid stimulating hormone on long-term salivary gland dysfunction in thyroid cancer patients treated with radioactive iodine. A systematic review. Oral Oncology 2023;136:106280 View
  2. Piciu D, Bran S, Moldovan M, Varvara S, Piciu A, Cuc S, Moisescu-Goia C, Barbus E, Mester A, Onisor F. Radioiodine-131 Therapy Used for Differentiated Thyroid Cancer Can Impair Titanium Dental Implants: An In Vitro Analysis. Cancers 2023;15(9):2558 View
  3. Baudin C, Bressand A, Buffet C, Menegaux F, Soret M, Lê A, Cardon T, Broggio D, Bassinet C, Huet C, Armengol G, Richardson D, Leenhardt L, Bernier M, Lussey-Lepoutre C. Dysfunction of the Salivary and Lacrimal Glands After Radioiodine Therapy for Thyroid Cancer: Results of the START Study After 6-Months of Follow-Up. Thyroid® 2023 View
  4. Villela R, Correa R. Lacrimal and Salivary Gland Dysfunction Following Radioiodine Therapy for Thyroid Cancer. Clinical Thyroidology® 2023;35(9):384 View
  5. Legrand A, Bernier M, Bressand A, Buffet C, Mandin C, Menegaux F, Soret M, Broggio D, Bassinet C, Huet C, Leenhardt L, Lussey-Lepoutre C, Baudin C. Health-related quality of life and radioiodine therapy in thyroid cancer patients: a before-and-after study. Quality of Life Research 2024;33(10):2721 View
  6. Dharia A, Desai K. Oral Health Monitoring: A Key Part of Thyroid Cancer Survivorship Care after Radioactive Iodine Treatment. Clinical Thyroidology® 2025;37(4):140 View
  7. Machado D, Bulzico D, Fontes L, Mello R, Locatelli S, Pujatti P. Real-world Data on Intermediate-risk Differentiated Thyroid Cancer Biochemical Response to 3700 or 5550 MBq of [131I]Sodium Iodide. Current Radiopharmaceuticals 2025;18(4):293 View
  8. Yu X, Li Z, Liu Y, Xu T, Chen Y. [68Ga]Ga-FAPI-04 PET/CT in the evaluation of radiation-induced salivary gland injury in head and neck cancer. European Journal of Nuclear Medicine and Molecular Imaging 2025 View